RESUMEN
PURPOSE: This study is aimed to assess the anti-cancer effects of Celecoxib and topotecan against Human Gastric cancer cell line (AGS) in comparison to the control in an in-vitro study. METHODS: In this experimental study, Celecoxib and topotecan was prepared at concentrations of 500, 250, 125, 62.5, 31.2, 15.6 and 7.8 mg/ml. The effect of celecoxib and topotecan separately and in mixed form were investigated on AGS and normal HEK cells. To investigate the cell survival, MTT method was used to study the pathway of apoptosis using flowcytometry and Caspase kits based on colorimetric. Finally, one-way ANOVA and t-test were used to analyze the data. RESULTS: The results of this study indicated that Celecoxib was cytotoxic against AGS and HEK cell lines. The topotecan indicated a significant cytotoxicity against AGS cells and was not toxic against HEK cell line. Our results indicated that Celecoxib and topotecan have synergist effects against AGS and HEK cell lines and were more effective than separate celecoxib or topotecan. CONCLUSION: The mixture of clecoxib and topotecan was more effective than celecoxib and topotecan in separate form. Our results indicated that use mixed forms of treatments can cause excellent therapeutic effects and can cause less side effects.